关于我们

Cloudbreak Pharma is a clinical-stage ophthalmic drug company with a proprietary technology, Multi-Kinase Inhibitors (MKI), that is de-risked with human clinical results and is uniquely suitable for both front-of-eye and back-of-eye diseases.

Under the MKI platform, Cloudbreak’s lead asset, the eye drop CBT-001, is in mid-Phase 3 in multiple regions for the treatment of pterygium, a disease impacting 15 million people in the US alone. Its second asset, CBT-004, is entering Phase 3 for pinguecula, a disease impacting about half of all people over age 70. CBT-001 and CBT-004 will potentially be the first and only FDA-approved drug therapies for these high-value conditions. The Company has additional technologies with pre-clinical through Phase 2 product candidates.

The Cloudbreak team is comprised of experienced ophthalmologic scientists and business professionals who are uniquely qualified to bring product candidates from pre-clinical to NDA approval.